Regen Biopharma Stock Price Prediction
| RGBPP Stock | USD 0.08 0.02 19.60% |
Oversold Vs Overbought
49
Oversold | Overbought |
Using Regen BioPharma hype-based prediction, you can estimate the value of Regen BioPharma from the perspective of Regen BioPharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Regen BioPharma to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Regen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Regen BioPharma after-hype prediction price | USD 0.08 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Regen |
Regen BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Regen BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Regen BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Regen BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Regen BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Regen BioPharma's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Regen BioPharma's historical news coverage. Regen BioPharma's after-hype downside and upside margins for the prediction period are 0.00 and 47.40, respectively. We have considered Regen BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Regen BioPharma is out of control at this time. Analysis and calculation of next after-hype price of Regen BioPharma is based on 3 months time horizon.
Regen BioPharma Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Regen BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regen BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Regen BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
6.03 | 47.32 | 0.00 | 0.26 | 0 Events / Month | 1 Events / Month | Within a week |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.08 | 0.08 | 0.50 |
|
Regen BioPharma Hype Timeline
Regen BioPharma is at this time traded for 0.08. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.26. Regen is projected to decline in value after the next headline, with the price expected to drop to 0.08. The average volatility of media hype impact on the company price is insignificant. The price reduction on the next news is expected to be -0.5%, whereas the daily expected return is at this time at 6.03%. The volatility of related hype on Regen BioPharma is about 110413.33%, with the expected price after the next announcement by competition of -0.18. About 55.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.02. Regen BioPharma had not issued any dividends in recent years. Assuming the 90 days horizon the next projected press release will be within a week. Check out Regen BioPharma Basic Forecasting Models to cross-verify your projections.Regen BioPharma Related Hype Analysis
Having access to credible news sources related to Regen BioPharma's direct competition is more important than ever and may enhance your ability to predict Regen BioPharma's future price movements. Getting to know how Regen BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Regen BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TSOI | Therapeutic Solutions International | (0.29) | 27 per month | 7.83 | (0.01) | 16.67 | (14.29) | 50.79 | |
| ACOGF | Alpha Cognition | 0.00 | 0 per month | 0.00 | 0.12 | 19.30 | (16.18) | 66,274 | |
| VGLS | Vg Life Sciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ADAG | Adagene | (0.01) | 6 per month | 0.00 | (0.04) | 8.13 | (9.52) | 37.93 | |
| MRZM | Marizyme | 0.00 | 0 per month | 9.63 | 0.12 | 50.00 | (20.00) | 128.57 | |
| MYMX | Mymetics Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PKTX | Protokinetix | 0.00 | 0 per month | 11.35 | 0.03 | 25.00 | (18.71) | 84.38 |
Regen BioPharma Additional Predictive Modules
Most predictive techniques to examine Regen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Regen using various technical indicators. When you analyze Regen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Regen BioPharma Predictive Indicators
The successful prediction of Regen BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Regen BioPharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Regen BioPharma based on analysis of Regen BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Regen BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Regen BioPharma's related companies.
Story Coverage note for Regen BioPharma
The number of cover stories for Regen BioPharma depends on current market conditions and Regen BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Regen BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Regen BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Regen BioPharma Short Properties
Regen BioPharma's future price predictability will typically decrease when Regen BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Regen BioPharma often depends not only on the future outlook of the potential Regen BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Regen BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.3 M | |
| Cash And Short Term Investments | 51.2 K |
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.